Out-licensing

Use of Human Protein C for Intraocular Fibrin and Inflammation Prevention

Prevention of intraocular fibrin deposition

A method of reducing and/or preventing intraocular fibrin deposition by administration of a pharmaceutically active dose of Protein C to an individual having elevated levels of intraocular fibrin.  Activated Protein C is a vitamin K- dependent plasma protein that modulates thrombosis by limiting coagulation and augmenting fibrinolysis. Studies demonstrate that eyes treated with activated protein C show a significant reduction in fibrin formation while maintaining corneal clarity. No signs of ocular toxicity have been noted.

Also provided are various methods of preventing intraocular fibrin formation, treating intraocular diseases and reducing intraocular inflammation.

94-08

Preclinical

U.S. Patent #6,656,490

U.S. Patent #6,872,404

Licensing Partner to commercialize this technology

License Status: Available for Exclusive Licensing

US6656490,US6872404